|
|
|
|
|
Sessions of Interest for the Upcoming 2021 Annual Meeting
|
|
|
|
|
|
| On Demand Educational Session |
|
|
|
|
|
New Development in Muscle-Invasive Disease
Presented By: Ronald De Wit, MD, Ph.D.
|
|
|
|
|
Is There an Optimal First-Line Combination Approach for Metastatic mRCC?
Presented By: Toni K. Choueiri, MD
|
|
|
|
|
| On Demand Special Symposium
|
|
|
|
|
|
Tissue and Blood-Based Biomarkers for Urothelial Cancer
Presented By: Matthew D. Galsky, MD
|
|
|
|
|
Incorporating Biomarkers into Clinical Trials
Presented By: Laurence Albiges, MD, Ph.D.
|
|
|
|
|
| On Demand Multidisciplinary Session
|
|
|
|
|
|
Systemic Treatments and Novel Approaches
Presented By: Silke Gillessen, MD
|
|
|
|
|
|
|
|
|
| Proffered Paper Session: Genitourinary Tumors, Non-Prostate 1 |
|
|
|
|
|
LBA27 - Erdafitinib (ERDA) or ERDA plus Cetrelimab (CET) for Patients with Metastatic or Locally Advanced Urothelial Carcinoma (mUC) and Fibroblast Growth Factor Receptor Alterations (FGFRa): First Phase (Ph) 2 Results from the NORSE Study
Presented By: Thomas Powles, MD, MBBS, MRCP
|
|
|
|
|
Invited Discussant LBA27
Presented By: Srikala Sridhar, MD, MS, FRCPC
|
|
|
|
|
|
|
|
|
| Proffered Paper Session: Genitourinary Tumors, Prostate |
|
|
|
|
|
LBA24 - Cabozantinib (C) in Combination with Atezolizumab (A) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results of Expanded Cohort 6 of the COSMIC-021 Study
Presented By: Neeraj Agarwal, MD
|
|
|
|
|
Invited Discussant LBA24
Presented By: Cora N. Sternberg, MD
|
|
|
|
|
|
|
LBA25 - Final Overall Survival (OS) Analysis from ARCHES: A Phase 3, Randomized, Double-Blind, Placebo (PBO)-Controlled Study of Enzalutamide (ENZA) + Androgen Deprivation Therapy (ADT) in Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Presented By: Andrew Armstrong, MD
Invited Discussant LBA25, Stephane M. Oudard (Paris, France)
Presented By: Stephane M. Oudard, MD, Ph.D.
|
|
|
|
|
|
|
|
|
|
| Mini Oral Session - Genitourinary Tumors, Non-Prostate
|
|
|
|
|
|
654MO - a Phase 2 Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Ducts Renal Cell Carcinoma: The BONSAI trial(Meeturo 2)
Presented By: Giuseppe Procopio, MD
|
|
|
|
|
Discussion 654MO, 655MO and 656MO
Presented By: Samra Turajlic, MD, Ph.D.
|
|
|
|
|
658MO - Cisplatin (Cis)-Related Immunomodulation and Efficacy with Atezolizumab (Atezo) + Cis- vs Carboplatin (Carbo)-Based Chemotherapy (Chemo) in Metastatic Urothelial Cancer (mUC)
Presented By: Matthew Galsky, MD
|
|
|
|
|
Discussion 657MO and 658MO
Presented By: Sumanta K. Pal, MD
|
|
|
|
|
659MO - Avelumab (A) as the Basis of Neoadjuvant Chemotherapy (NAC) Regimen in Platinum Eligible and Ineligible Patients (Pts) with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC)
Presented By: Nieves Martinez Chanza, MD
|
|
|
|
|
LBA31 - High- vs Low-Dose Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced Urothelial Cancer (NABUCCO Cohort 2)
Presented By: Jeroen Van Dorp, MD
|
|
|
|
|
|
|
|
|
| Proffered Paper Session: Genitourinary Tumors, Non-Prostate 2 |
|
|
|
|
|
LBA28: STAR. A Randomised Multi-Stage Phase II/III Trial of Standard first-line therapy (sunitinib or pazopanib) Comparing Temporary Cessation with Allowing Continuation, in the treatment of locally advanced and/or metastatic Renal Cancer (RCC)
Presented By: Janet Brown MBBS, MSc, MD, FRCP
|
|
|
|
|
LBA29: Nivolumab in Combination with Alternatively Scheduled Ipilimumab in First-Line Treatment of Patients with Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Presented By: Naveen S. Vasudev, Ph.D., MRCP, MBChB, BMSc (Hons)
|
|
|
|
|
653O: Pembrolizumab (Pembro) vs Placebo as Adjuvant Therapy for Patients (Pts) with Renal Cell Carcinoma (RCC): Patient-Reported Outcomes (PRO) in KEYNOTE-564
Presented By: Toni K. Choueiri, MD, Ph.D.
|
|
|
|
|
Invited Discussant LBA28, LBA29 and 653O
Presented By: Brian I. Rini, MD
|
|
|
|
|
LBA30: Single-Dose Carboplatin Followed by Involved-Node Radiotherapy as Curative Treatment for Seminoma Stage IIA/B: Efficacy Results from the International Multicenter Phase II Trial SAKK 01/10
Presented By: Alexandros Papachristofilou, MD
|
|
|
|
Invited Discussant LBA30
Presented By: Christian K. Kollmannsberger, MD, FRCPC
|
|
|
|
|
|
|
|
|
LBA4: Abiraterone Acetate plus Prednisolone (AAP) with or Without Enzalutamide (ENZ) Added to Androgen Deprivation Therapy (ADT) Compared to ADT Alone for Men with High-Risk Non-Metastatic (M0) Prostate Cancer (PCa): Combined Analysis from Two Comparisons in the STAMPEDE Platform Protocol
Presented By: Gerhardt Attard, MD, Ph.D.
LBA5: A Phase 3 Trial with a 2x2 Factorial Design in Men with De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival with Abiraterone Acetate plus Prednisone in PEACE-1
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
|
|
|
|
|
Invited Discussant LBA4 and LBA5
Presented By: Eleni Efstathiou, MD, Ph.D.
|
|
|
|
|
| Mini Oral Session - Genitourinary Tumors, Prostate |
|
|
|
|
|
576MO - Health-Related Quality of Life (HRQoL), Pain and Safety Outcomes in the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
578MO - Phase 1b/2 Study of Sabizabulin (VERU-111), an Androgen Receptor Transport Disruptor, in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Failed an Androgen Receptor Targeting Agent (ARTA)
Presented By: Mark C. Markowski, MD, Ph.D.
|
|
|
|
|
579MO - CheckMate 9KD Cohort A2 Final Analysis: Nivolumab (NIVO) + Rucaparib for Chemotherapy (CT)-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Presented By: Daniel P. Petrylak, MD
|
|
|
|
|
Discussion 578MO and 579MO
Presented By: Giulia Baciarello, MD
|
|
|
|
|
|
|
|
|
|
|
| Enhanced androgen signaling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
|
|
|
|
|
Yes
Presented By: Karim Fizazi, MD, Ph.D.
|
|
|
|
|
No
Presented By: Ronald De Wit, MD, Ph.D.
|
|
|
|
|
|
|
| Are adjuvant immune checkpoint inhibitors a standard of care for operable high-risk urothelial and kidney cancer? |
|
|
|
|
Yes
Presented By: Thomas Powles, MD, PhD, MRCP
|
|
|
|
|
No
Presented By: Michiel S. Van der Heijden, MD, Ph.D.
|
|
|
|
|
|
|
|
|
| On Demand ePosters: Genitourinary tumors, prostate |
|
|
|
|
|
581P - Patient (Pt) Reported Pain in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) Receiving Talazoparib (TALA): TALAPRO-1
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
582P - Health-Related Quality of Life (HRQoL) at Final Analysis of the GALAHAD Study of Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and DNA Repair Defects (DRD)
Presented By: Matthew R. Smith, MD, Ph.D.
|
|
|
|
|
621P - Efficacy and Safety of Relugolix vs Leuprolide (LEU) in Men with Advanced Prostate Cancer (APC): Clinical Subgroup Analysis from the Phase 3 HERO Study
Presented By: Bertrand Tombal, MD, Ph.D.
|
|
|
|
|
647TiP - PSMAddition: A Phase 3 Trial to Compare Treatment with 177Lu-PSMA-617 plus Standard of Care (SOC) Versus SOC Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Presented By: Scott Tagawa, MD, MS, FACP
|
|
|
|
|
648TiP - PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment with a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients with mCRPC
Presented By: Michael J. Morris, MD
|
|
|
|
|
|
|
|
